Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

bioMérieux S.A.. (1/22/15). "Press Release: Business Review for the Three Months and Full Year Ended December 31, 2014". Marcy l’Étoile.

Organisations Organisation bioMérieux S.A. (Euronext: BIM)
  Group Mérieux (Group)
  Organisation 2 BioFire Diagnostics Inc.
  Today BioFire Diagnostics LLC
  Group Mérieux (Group)
Products Product in vitro diagnostics (IVD)
  Product 2 FilmArray® 2.0 PCR system
  Index term 2 BioFire Diagnostics–Mérieux: investment, 201309–201401 acquisition 100% for $540m in cash by bioMérieux
Person Person Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology)

Sales: solid growth, lifted sharply by BioFire

> Revenue: €1,698 million, up a reported 7%
> Up 8.7%, including BioFire and at constant exchange rates
> Up 3.8% at constant exchange rates and scope of consolidation, in line with the full-year target

Operations: significant headway

> BioFire
Fast 60% growth in sales, led by the respiratory panel
Preparations underway to launch the higher-throughput FilmArray® 2.0 system
> Production conditions at the Durham site restored

Strategy: major milestones reached during the quarter

> Automated clinical microbiology: strategic partnership with Copan
> Next Generation Sequencing: collaboration with Illumina
> High medical value assays: agreement with Astute Medical
> Food-related molecular virology tests: acquisition of CEERAM

Organic growth in sales expected to accelerate in 2015

“In 2014, bioMérieux stepped up implementation of its strategic plan, in particular with the acquisition of BioFire in molecular biology, and redeployed its operational organization,” said Chairman Jean-Luc Belingard. “With outcomes in line with the objectives set early in the year, I am especially pleased with the progress made by our Company under the leadership of our new Management Committee, headed by Chief Executive Officer Alexandre Mérieux.”

“Today, bioMérieux announced sales growth at constant exchange rates of nearly 9% and of 3.8% at constant scope of consolidation,” said Chief Executive Officer Alexandre Mérieux. “Our sales performance was in line with the target set early in the year, reflecting our competitiveness and ability to adjust to changing market conditions. In addition, with the signature of eight business development agreements in 2014, we reached decisive milestones in the deployment of our roadmap. This robust strategic and operational dynamic, combined with our solid fundamentals, sustained favorable momentum in North America and expanding product portfolio, especially in molecular biology and automated microbiology, enables us to expect sales to accelerate in 2015, and growth of between 4.5% and 6.5% at constant exchange rates and scope of consolidation.”

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2014.


Consolidated sales rose by 8.7% year-on-year at constant exchange rates in 2014, including €78 million in sales from BioFire as from January 16. Organic growth (i.e. at constant exchange rates and scope of consolidation) came to 3.8% for the year. The recent appreciation of the U.S. dollar against the euro helped to limit the negative currency effect to €28 million, or 180 basis points of growth. In this environment, sales for the year amounted to €1,698 million, up a reported 7% from €1,588 million in 2013.

Download [ of full release at ]

Record changed: 2016-03-20


Picture [iito] Plain Stupid Simple 650x80px

More documents for Mérieux (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

» top